Organization
Universitätsspital Basel, Rheumatology, Basel, Switzerland
3 abstracts
Abstract
A NOVEL TLR7/8 ANTAGONIST BLOCKS PRO-INFLAMMATORY FUNCTION OF IMMUNE COMPLEXES FROM LUPUS PATIENTS AND ABROGATES LUPUS-LIKE DISEASE IN MICEOrg: Novartis Institute of Biomedical Research, Immunology, Basel, Switzerland, UNICAMP Universidade Estadual de Campinas, School of Medicine, Orthopedics, Rheumatology and Traumatology, Campinas, Brazil, Universitätsspital Basel, Rheumatology, Basel, Switzerland, Cincinnati Children’s Hospital Medical Center, Rheumatology, Cincinnati, United States of America, Novartis Institute of Biomedical Research, Cancer Research, San Diego, United States of America,
Abstract
ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, Deepscover, Biostatistics, Puteaux, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Schulthess Klinik, Universitätsspital Basel, Rheumatology, Basel, Switzerland,
Abstract
ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTINGOrg: Bristol Myers Squibb, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, University of Leeds, University of Manchester and The Christie NHS Foundation Trust, Evangelical Hospital, Department of Internal Medicine, Vienna, Austria,